{"id":"placebo-fluticasone","safety":{"commonSideEffects":[]},"_chembl":{"chemblId":"CHEMBL1676","moleculeType":"Small molecule","molecularWeight":"538.58"},"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=Placebo fluticasone","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T02:32:27.436919+00:00"},"aiSummary":{"url":"","method":"ai_extraction","source":"AI Strategic Summary","aiModel":"featherless","rawText":"","confidence":0.9,"sourceType":"ai_extraction","retrievedAt":"2026-04-20T02:32:42.133926+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T02:32:33.316301+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Placebo fluticasone","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T02:32:33.708773+00:00"},"mechanism.target_chembl":{"url":"","method":"api_direct","source":"ChEMBL mechanism: Glucocorticoid receptor agonist","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T02:32:34.878477+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL1676/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T02:32:34.545224+00:00"}},"_dailymed":null,"aiSummary":"Placebo fluticasone is a nasal spray used in clinical trials to compare its safety and efficacy with other treatments for conditions such as seasonal allergic rhinitis, asthma, and perennial allergic rhinitis. It is a component of a study comparing two steroid treatments for the relief of symptoms of seasonal allergic rhinitis, as identified by ClinicalTrials.gov.","mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Placebo fluticasone is a non-active comparator used in randomized controlled trials to evaluate the efficacy of active fluticasone formulations. It contains no active pharmaceutical ingredient and serves as a control to distinguish true drug effects from placebo response. Any observed effects in the placebo group are attributable to placebo response rather than pharmacological action.","oneSentence":"Placebo fluticasone has no active pharmacological effect, as it is an inert control formulation used in clinical trials.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:00:42.559Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"_validation":{"fieldsValidated":1,"lastValidatedAt":"2026-04-20T02:32:42.134004+00:00","fieldsConflicting":0,"overallConfidence":0.95},"indications":{"approved":[{"name":"Control arm in clinical trials evaluating fluticasone efficacy in allergic rhinitis, asthma, or other respiratory conditions"}]},"trialDetails":[{"nctId":"NCT06676319","phase":"PHASE2","title":"Study of Lunsekimig (SAR443765) Compared With Placebo in Adults With High-risk Asthma","status":"RECRUITING","sponsor":"Sanofi","startDate":"2024-11-07","conditions":"Asthma","enrollment":1147},{"nctId":"NCT06850805","phase":"PHASE3","title":"Efficacy and Safety of 186 mcg of OPN-375 Nasal Spray Twice a Day (BID) in Adolescents With Chronic Rhinosinusitis Without Nasal Polyps","status":"RECRUITING","sponsor":"Optinose US Inc.","startDate":"2025-07-28","conditions":"Chronic Rhinosinusitis Without Nasal Polyps","enrollment":84},{"nctId":"NCT06664619","phase":"PHASE3","title":"A Randomized, Double-Blind, Placebo-Controlled Trial on Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Combination in Participants 12 Years and Older With Asthma","status":"RECRUITING","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2024-12-12","conditions":"Asthma","enrollment":724},{"nctId":"NCT05275686","phase":"PHASE2","title":"Effect of Novel Exhalational Delivery System With Fluticasone (EDS-FLU) on Eustachian Tube Dysfunction (ETD)","status":"RECRUITING","sponsor":"Cedars-Sinai Medical Center","startDate":"2022-04-20","conditions":"Eustachian Tube Dysfunction","enrollment":80},{"nctId":"NCT07223294","phase":"PHASE3","title":"Study to Evaluate the Therapeutic Equivalence and Safety of Fluticasone Furoate and Vilanterol Inhalation Powder 100 mcg/25 mcg and BREO ELLIPTA 100 mcg/25 mcg in Participants With Asthma","status":"NOT_YET_RECRUITING","sponsor":"Sandoz","startDate":"2026-04","conditions":"Respiratory","enrollment":1430},{"nctId":"NCT05776927","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of QVM149 (Indacaterol Acetate / Glycopyrronium Bromide / Mometasone Furoate) Versus Salmeterol Xinafoate/Fluticasone Propionate in Children From 12 Years to Less Than 18 Years of Age With Asthma.","status":"NOT_YET_RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2026-05-29","conditions":"Asthma","enrollment":304},{"nctId":"NCT06572228","phase":"PHASE4","title":"Efficacy of Dupilumab Added to Medium Dose Inhaled Corticosteroid/Long-acting Beta-agonist (ICS/LABA) in Comparison to ICS Dose Escalation to High Dose ICS/LABA in Adolescent and Adult Patients With Uncontrolled Asthma","status":"RECRUITING","sponsor":"Regeneron Pharmaceuticals","startDate":"2024-08-26","conditions":"Asthma","enrollment":250},{"nctId":"NCT05299086","phase":"PHASE3","title":"As Needed Versus Regular Intranasal Corticosteroid in Children With Perennial Allergic Rhinitis","status":"COMPLETED","sponsor":"Mahidol University","startDate":"2022-04-04","conditions":"Perennial Allergic Rhinitis, Child, Only","enrollment":68},{"nctId":"NCT04885530","phase":"PHASE3","title":"ACTIV-6: COVID-19 Study of Repurposed Medications","status":"COMPLETED","sponsor":"Susanna Naggie, MD","startDate":"2021-06-08","conditions":"Covid19","enrollment":10956},{"nctId":"NCT06040268","phase":"PHASE1, PHASE2","title":"Advair HFA in Healthy and HAPE Predisposed Subjects","status":"RECRUITING","sponsor":"University of Colorado, Denver","startDate":"2023-12-12","conditions":"Altitude Edema","enrollment":60},{"nctId":"NCT04655508","phase":"PHASE3","title":"Efficacy of Fluticasone Propionate Associated With Salmeterol Using Inhalation Chamber Versus Placebo to Improve the Respiratory Function in Children Over Six Years of Age Who Underwent Allogeneic Hematopoietic Stem Cell Transplantation With a Decline of FEV1 ≥10% From Pre Transplantation","status":"TERMINATED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2021-05-21","conditions":"Stem Cell Transplant Complications, Respiratory Disease, Bronchiolitis Obliterans","enrollment":35},{"nctId":"NCT05634746","phase":"PHASE3","title":"24-Week Induction Study of APT-1011 in Adult Subjects With Eosinophilic Esophagitis (EoE) (FLUTE 3)","status":"COMPLETED","sponsor":"Ellodi Pharmaceuticals, LP","startDate":"2022-12-29","conditions":"Eosinophilic Esophagitis","enrollment":218},{"nctId":"NCT07114107","phase":"NA","title":"Vibroacoustic Therapy With Oscillating Positive Expiratory Pressure in the Treatment of Nasal Congestion","status":"NOT_YET_RECRUITING","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2025-08","conditions":"Atopic Rhinitis, Atopic Asthma","enrollment":200},{"nctId":"NCT05545072","phase":"PHASE3","title":"Add-on Dupilumab for AFRS as Postoperative Therapy (ADAPT)","status":"TERMINATED","sponsor":"Emory University","startDate":"2023-10-26","conditions":"Allergic Fungal Rhinosinusitis","enrollment":5},{"nctId":"NCT06066606","phase":"NA","title":"U-LABA/ICS Effects on Exercise Performance, Vilanterol","status":"RECRUITING","sponsor":"Morten Hostrup, PhD","startDate":"2023-10-03","conditions":"Exercise Performance","enrollment":30},{"nctId":"NCT06077019","phase":"NA","title":"Role of Lung Function for Exercise Capacity in Well-trained Individuals","status":"RECRUITING","sponsor":"Morten Hostrup, PhD","startDate":"2023-10-03","conditions":"Exercise Performance","enrollment":60},{"nctId":"NCT01396278","phase":"PHASE2","title":"Study on BI 54903 (Inhaled Corticosteroid) Administered Twice Daily Via Respimat Inhaler in Patients With Asthma Inadequately Controlled on Medium Dose Inhaled Corticosteroid (ICS).","status":"TERMINATED","sponsor":"Boehringer Ingelheim","startDate":"2011-07-01","conditions":"Asthma","enrollment":9},{"nctId":"NCT02630121","phase":"PHASE4","title":"Effect of Oxymetazoline Hydrochloride in Combination With Fluticasone Propionate on the Apnea Hypopnea Index (AHI) in Subject With Persistent Nasal Congestion and Mild Obstructive Sleep Apnea","status":"RECRUITING","sponsor":"University of South Florida","startDate":"2023-04-01","conditions":"Sleep Apnea, Chronic Nasal Congestion","enrollment":52},{"nctId":"NCT02402465","phase":"PHASE4","title":"Factors Involved in Dymista's Superior Clinical Efficacy in the Treatment of Seasonal Allergic Rhinitis","status":"COMPLETED","sponsor":"University of Chicago","startDate":"2015-02","conditions":"Allergic Rhinitis","enrollment":22},{"nctId":"NCT00394355","phase":"PHASE4","title":"Effects of Mometasone Furoate Dry Powder Inhaler, Fluticasone Propionate, and Montelukast on Bone Mineral Density in Asthmatics (Study P03418)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2006-09","conditions":"Asthma","enrollment":566},{"nctId":"NCT00127166","phase":"PHASE3","title":"Two Investigational Drugs in the Prevention of Airway Constriction Brought on by Exercise in Participants With Asthma (0476-911)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2005-12","conditions":"Exercise Induced Asthma","enrollment":154},{"nctId":"NCT00284856","phase":"PHASE3","title":"Montelukast Asthmatic Smoker Study (0476-332)(COMPLETED)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2006-05","conditions":"Asthma","enrollment":1640},{"nctId":"NCT02889809","phase":"PHASE4","title":"Effects of a Orally Inhaled Fluticasone Furoate on Growth Velocity in Prepubertal, Paediatric Subjects With Asthma Over a Year","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2017-07-10","conditions":"Asthma","enrollment":477},{"nctId":"NCT01484210","phase":"PHASE3","title":"Single Dose Study of the Fluticasone/Salmeterol (500/50 μg) Administered With Elpenhaler® Versus Diskus®","status":"COMPLETED","sponsor":"Elpen Pharmaceutical Co. Inc.","startDate":"2008-03","conditions":"Asthma","enrollment":28},{"nctId":"NCT00576069","phase":"","title":"Mechanism(s)of Airflow Limitation in Moderate-severe Persistent Asthma","status":"RECRUITING","sponsor":"Gelb, Arthur F., M.D.","startDate":"2007-10-25","conditions":"Asthma","enrollment":60},{"nctId":"NCT05083312","phase":"PHASE3","title":"Efficacy and Safety APT-1011 in Adolescent Subjects With Eosinophilic Esophagitis (EoE) - A Sub-Study of the FLUTE-2 Trial","status":"COMPLETED","sponsor":"Ellodi Pharmaceuticals, LP","startDate":"2021-09-30","conditions":"Eosinophilic Esophagitis","enrollment":6},{"nctId":"NCT03926026","phase":"PHASE2","title":"Study Evaluating the Safety and Tolerability of NCX 4251 for the Treatment of Acute Exacerbations of Blepharitis","status":"COMPLETED","sponsor":"Nicox Ophthalmics, Inc.","startDate":"2019-03-18","conditions":"Blepharitis","enrollment":36},{"nctId":"NCT05736874","phase":"PHASE3","title":"ACTIV-6: COVID-19 Study of Repurposed Medications - Arm C (Fluticasone)","status":"COMPLETED","sponsor":"Susanna Naggie, MD","startDate":"2021-08-06","conditions":"Covid19","enrollment":1407},{"nctId":"NCT04281108","phase":"PHASE3","title":"Efficacy and Safety APT-1011 in Adult Subjects With Eosinophilic Esophagitis (EoE) (FLUTE-2)","status":"COMPLETED","sponsor":"Ellodi Pharmaceuticals, LP","startDate":"2020-01-30","conditions":"Eosinophilic Esophagitis","enrollment":143},{"nctId":"NCT02246920","phase":"PHASE3","title":"Clinical Equivalence Study of Fluticasone Propionate Nasal Spray, 50 mcg/Actuation vs. Flonase in Allergic Rhinitis Patients","status":"TERMINATED","sponsor":"Teva Pharmaceuticals USA","startDate":"2014-03-01","conditions":"Seasonal Allergic Rhinitis","enrollment":1474},{"nctId":"NCT00995475","phase":"PHASE4","title":"A Proof of Concept Study to Evaluate the Dose Response for the Systemic Benefit Risk Ratio of Inhaled Fluticasone Propionate in Chronic Obstructive Pulmonary Disease","status":"COMPLETED","sponsor":"University of Dundee","startDate":"2006-10","conditions":"COPD","enrollment":18},{"nctId":"NCT04072887","phase":"PHASE2","title":"Dose-range Finding Efficacy and Safety Study for QBW251 in COPD Patients","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2019-09-12","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":974},{"nctId":"NCT03191864","phase":"PHASE2","title":"Efficacy, Safety, and Pharmacokinetics of APT-1011 in Subjects With Eosinophilic Esophagitis (EoE)","status":"COMPLETED","sponsor":"Adare Pharmaceuticals, Inc.","startDate":"2017-06-22","conditions":"Eosinophilic Esophagitis","enrollment":106},{"nctId":"NCT04665895","phase":"PHASE3","title":"A Clinical Trial for Examining the Therapeutic Equivalence Between Fluticasone Propionate 100 mcg/Blister Oral Inhalation Powder/Respirent Pharmaceuticals vs. FLOVENT DISKUS® 100mcg/Blister Oral Inhalation Powder/GSK in Patients With Asthma","status":"COMPLETED","sponsor":"Respirent Pharmaceuticals Co Ltd.","startDate":"2020-12-09","conditions":"Asthma","enrollment":451},{"nctId":"NCT04652245","phase":"PHASE4","title":"Dymista Allergen Chamber - Onset of Action Study","status":"COMPLETED","sponsor":"MEDA Pharma GmbH & Co. KG","startDate":"2020-12-14","conditions":"Seasonal Allergic Rhinitis","enrollment":216},{"nctId":"NCT05664061","phase":"PHASE3","title":"Bioequivalence With Clinical Endpoint Study of Fluticasone Propionate 100 mcg and Salmeterol 50 mcg Inhalation Powder/Respirent Pharmaceuticals vs. ADVAIR DISKUS® 100/50 mcg Inhalation Powder/GSK in Patients With Asthma","status":"UNKNOWN","sponsor":"Respirent Pharmaceuticals Co Ltd.","startDate":"2023-01-30","conditions":"Asthma","enrollment":451},{"nctId":"NCT05459194","phase":"NA","title":"Efficacy and Safety Study of Fluticasone/Salmeterol Administered With Elpenhaler","status":"COMPLETED","sponsor":"Elpen Pharmaceutical Co. Inc.","startDate":"2008-10","conditions":"Asthma","enrollment":42},{"nctId":"NCT01397162","phase":"PHASE2","title":"Dose Finding Study on BI54903 (Inhaled Corticosteroid) Administered Twice Daily Via Respimat® Inhaler in Asthmatic Patients Inadequately Controlled on Short-acting-beta-agonist (SABA) Therapy","status":"TERMINATED","sponsor":"Boehringer Ingelheim","startDate":"2011-07-21","conditions":"Asthma","enrollment":29},{"nctId":"NCT01397201","phase":"PHASE2","title":"Study on BI 54903 (Inhaled Corticosteroid) Administered Twice Daily Via Respimat Inhaler in Patients With Asthma Inadequately Controlled on Low Dose Inhaled Corticosteroid (ICS)","status":"TERMINATED","sponsor":"Boehringer Ingelheim","startDate":"2011-07-01","conditions":"Asthma","enrollment":30},{"nctId":"NCT03387852","phase":"PHASE2","title":"Evaluation of SAR440340 and as Combination Therapy With Dupilumab in Moderate-to-Severe Asthma Participants","status":"COMPLETED","sponsor":"Sanofi","startDate":"2018-03-12","conditions":"Asthma","enrollment":296},{"nctId":"NCT01092143","phase":"PHASE2","title":"BI 671800 ED in Steroid-naive Asthmatic Patients","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2010-03-18","conditions":"Asthma","enrollment":389},{"nctId":"NCT01103349","phase":"PHASE2","title":"BI 671800 in Asthmatic Patients on Inhaled Corticosteroids","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2010-04-20","conditions":"Asthma","enrollment":243},{"nctId":"NCT05363202","phase":"PHASE3","title":"To Study Generic Fluticasone Propionate Inhalation Aerosol for the Treatment of Bronchial Asthma","status":"UNKNOWN","sponsor":"Glenmark Pharmaceuticals Ltd. India","startDate":"2022-04-15","conditions":"Bronchial Asthma","enrollment":790},{"nctId":"NCT02874144","phase":"PHASE2","title":"Anti-Inflammatory Agent in Sinusitis","status":"COMPLETED","sponsor":"Northwestern University","startDate":"2016-06-20","conditions":"Nasal Polyps","enrollment":43},{"nctId":"NCT01090024","phase":"PHASE2","title":"Bi 671800 in Asthmatic Patients on Inhaled Corticosteroids","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2010-03-01","conditions":"Asthma","enrollment":108},{"nctId":"NCT02573233","phase":"PHASE2","title":"Evaluation of Dupilumab's Effects on Airway Inflammation in Patients With Asthma","status":"COMPLETED","sponsor":"Sanofi","startDate":"2016-01-27","conditions":"Asthma","enrollment":42},{"nctId":"NCT02245672","phase":"PHASE3","title":"MGR001 / Advair Diskus Local Equivalence Study in Asthma","status":"COMPLETED","sponsor":"Mylan Pharma UK Ltd.","startDate":"2014-10","conditions":"Asthma","enrollment":1128},{"nctId":"NCT03599791","phase":"PHASE3","title":"DYmista NAsal Spray in CHInese Patients","status":"COMPLETED","sponsor":"MEDA Pharma GmbH & Co. KG","startDate":"2018-06-29","conditions":"Allergic Rhinitis","enrollment":900},{"nctId":"NCT03004131","phase":"PHASE4","title":"MP-AzeFlu Allergen Chamber - Onset of Action Study","status":"COMPLETED","sponsor":"MEDA Pharma GmbH & Co. KG","startDate":"2017-01-07","conditions":"Seasonal Allergic Rhinitis","enrollment":82},{"nctId":"NCT00540839","phase":"PHASE3","title":"A Study of Montelukast (MK-0476) Compared With Fluticasone in Pediatric Participants With Chronic Asthma (MK-0476-303)","status":"WITHDRAWN","sponsor":"Organon and Co","startDate":"2007-11","conditions":"Asthma, Bronchial","enrollment":""},{"nctId":"NCT03882047","phase":"PHASE3","title":"Mometasone Furoate Aqueous (MK-0887/SCH 032088) Nasal Spray vs Placebo and FLONASE® in Seasonal Allergic Rhinitis Patients (I94-001)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"1994-08-11","conditions":"Rhinitis, Allergic, Seasonal","enrollment":313},{"nctId":"NCT00783224","phase":"PHASE3","title":"A Comparative Study of Mometasone Furoate Nasal Spray and Fluticasone Propionate Nasal Spray in Patients With Perennial Allergic Rhinitis (Study P04512)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2005-09","conditions":"Perennial Allergic Rhinitis","enrollment":351},{"nctId":"NCT02139644","phase":"PHASE3","title":"Study of Fluticasone Propionate MDPI Compared With Fluticasone/Salmeterol MDPI in Adolescent and Adult Patients With Persistent Asthma","status":"COMPLETED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2014-06","conditions":"Asthma","enrollment":787},{"nctId":"NCT02180672","phase":"PHASE3","title":"Steroids for Pediatric Apnea Research in Kids","status":"COMPLETED","sponsor":"Children's Hospital of Philadelphia","startDate":"2014-09","conditions":"Obstructive Sleep Apnea Syndrome","enrollment":211},{"nctId":"NCT02141854","phase":"PHASE3","title":"Efficacy and Safety Study of FP MDPI Compared With FS MDPI in Adolescent and Adult Patients With Persistent Asthma","status":"COMPLETED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2014-06","conditions":"Asthma","enrollment":882},{"nctId":"NCT02980133","phase":"PHASE3","title":"Study of Fluticasone Propionate Multidose Dry Powder Inhaler Compared With Fluticasone Propionate/Salmeterol Multidose Dry Powder Inhaler","status":"COMPLETED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2016-12-28","conditions":"Asthma","enrollment":841},{"nctId":"NCT01738087","phase":"PHASE2","title":"Lung Bioavailability and Total Systemic Exposure to Beclomethasone17MonoPropionate and Formoterol Across Two Strengths of NEXThaler Inhalation Powder","status":"COMPLETED","sponsor":"Chiesi Farmaceutici S.p.A.","startDate":"2012-11","conditions":"Asthmatic","enrollment":30},{"nctId":"NCT02230696","phase":"PHASE3","title":"Comparative Safety and Efficacy of Two Steroid Treatments in the Relief of the Symptoms of Seasonal Allergic Rhinitis","status":"COMPLETED","sponsor":"Padagis LLC","startDate":"2014-08","conditions":"Seasonal Allergic Rhinitis","enrollment":951},{"nctId":"NCT03468790","phase":"PHASE3","title":"Anti-IgE Monoclonal Antibody Treatment in Patients With Allergic Asthma.","status":"COMPLETED","sponsor":"Shanghai Biomabs Pharmaceutical Co., Ltd.","startDate":"2018-05-09","conditions":"Asthma, Allergic","enrollment":393},{"nctId":"NCT03756883","phase":"PHASE3","title":"Therapeutic Equivalence of Two Formulations of Fluticasone Propionate and Salmeterol Inhalation Powder in Subjects With Asthma","status":"COMPLETED","sponsor":"Actavis Inc.","startDate":"2018-12-03","conditions":"Asthma","enrollment":999},{"nctId":"NCT02609126","phase":"PHASE1","title":"Safety Study of a Long-Acting Injectable Steroid to Treat Knee Osteoarthritis","status":"COMPLETED","sponsor":"Eupraxia Pharmaceuticals Inc.","startDate":"2016-04","conditions":"Osteoarthritis, Knee","enrollment":32},{"nctId":"NCT03879837","phase":"PHASE3","title":"Therapeutic Equivalence of Fluticasone Propionate Pressurized Metered Dose Inhaler, 110 mcg, to Flovent® HFA 110 mcg","status":"COMPLETED","sponsor":"Actavis Inc.","startDate":"2019-03-25","conditions":"Asthma","enrollment":1902},{"nctId":"NCT03474081","phase":"PHASE4","title":"A Comparative Study Between Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Single Inhaler Triple Therapy Versus Tiotropium Monotherapy in Subjects With Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2018-03-29","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":800},{"nctId":"NCT01439815","phase":"PHASE4","title":"An Allergen BioCube (ABC) Study Evaluating the Efficacy of Fluticasone Propionate Nasal Spray Compared to Placebo","status":"COMPLETED","sponsor":"ORA, Inc.","startDate":"2011-09","conditions":"Allergic Rhinitis, Allergic Conjunctivitis","enrollment":22},{"nctId":"NCT04750603","phase":"PHASE4","title":"Effect of Fluticasone Furoate/Vilanterol on EIA in Adolescents","status":"COMPLETED","sponsor":"Rambam Health Care Campus","startDate":"2018-12-01","conditions":"Asthma in Children","enrollment":92},{"nctId":"NCT01279057","phase":"PHASE3","title":"A Study Comparing Two Fluticasone Furoate Nasal Sprays in the Relief of the Signs and Symptoms of Seasonal Allergic Rhinitis","status":"COMPLETED","sponsor":"Sandoz","startDate":"2010-12-27","conditions":"Rhinitis, Allergic, Seasonal","enrollment":727},{"nctId":"NCT02424539","phase":"PHASE4","title":"A Study to Compare the Efficacy and Safety of Fluticasone Furoate Nasal Sprays (FFNS) 55 Microgram (mcg) and 110 mcg in Chinese Pediatric Subjects With Allergic Rhinitis (AR)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2015-09-30","conditions":"Rhinitis, Allergic, Perennial and Seasonal, Rhinitis, Allergic","enrollment":358},{"nctId":"NCT01253603","phase":"PHASE2","title":"Efficacy, Safety, and Pharmacokinetics of QAW039","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2010-11","conditions":"Persistent Asthma","enrollment":170},{"nctId":"NCT00929968","phase":"PHASE2","title":"Safety, Tolerability and Pharmacokinetics of Multiple Doses of VAK694 in Atopic Subjects With Seasonal Rhinitis","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2009-06","conditions":"Allergic Rhinitis","enrollment":35},{"nctId":"NCT03622112","phase":"PHASE2","title":"A Study to Assess the Efficacy and Safety of Multiple Dose Levels of AZD7594 Administered Once Daily by Inhalation in Asthmatic Subjects","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2019-01-02","conditions":"Asthma","enrollment":808},{"nctId":"NCT03012061","phase":"PHASE2","title":"Phase IIb Study of Umeclidinium (UMEC) Bromide Versus Placebo in Subjects With Asthma","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2017-01-25","conditions":"Asthma","enrollment":425},{"nctId":"NCT03478696","phase":"PHASE4","title":"A Randomized Study, Comparing Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC /VI) Single Inhaler Triple Therapy, Versus Multiple Inhaler Therapy (Budesonide/Formoterol Plus Tiotropium) in Subjects With Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2018-06-25","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":732},{"nctId":"NCT03478683","phase":"PHASE4","title":"A Randomized Study, Comparing Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Single Inhaler Triple Therapy, Versus Multiple Inhaler Therapy (Budesonide/Formoterol Plus Tiotropium) in Subjects With Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2018-06-25","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":729},{"nctId":"NCT00426283","phase":"PHASE2","title":"A Study of Flovent in Patients With Eosinophilic Esophagitis","status":"COMPLETED","sponsor":"Marc Rothenberg, MD","startDate":"2007-01","conditions":"Eosinophilic Esophagitis","enrollment":42},{"nctId":"NCT01578278","phase":"PHASE2","title":"Bepotastine Besilate-corticosteroid Nasal Spray Combination Compared to Placebo, Bepotastine Besilate Nasal Spray, and Corticosteroid Nasal Spray in the Treatment of Patients With Seasonal Allergic Rhinitis","status":"COMPLETED","sponsor":"Bausch & Lomb Incorporated","startDate":"2011-12","conditions":"Seasonal Allergic Rhinitis","enrollment":606},{"nctId":"NCT03394989","phase":"PHASE3","title":"BE Study of Fluticasone Propionate/Salmeterol Inhalation Powder in Asthma Patients","status":"COMPLETED","sponsor":"Cipla Ltd.","startDate":"2018-10-17","conditions":"Bronchial Asthma","enrollment":1366},{"nctId":"NCT02748070","phase":"NA","title":"Perioperative Oral Steroids for Chronic Rhinosinusitis Without Polyps (CRSsNP)","status":"COMPLETED","sponsor":"Stanford University","startDate":"2015-08","conditions":"Chronic Rhinosinusitis, Endoscopic Sinus Surgery, Chronic Rhinosinusitis Without Polyps","enrollment":81},{"nctId":"NCT02991859","phase":"PHASE2","title":"Phase 2a, AMP Challenge, Dose Escalation Study to Assess the Dose Response for Topical Efficacy and Systemic Activity in Asthmatic Subjects","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2017-02-09","conditions":"Asthma","enrollment":56},{"nctId":"NCT02573870","phase":"PHASE2","title":"Batefenterol/Fluticasone Furoate in Treatment of Chronic Obstructive Pulmonary Disease","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2015-12-01","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":63},{"nctId":"NCT03676413","phase":"PHASE3","title":"A Clinical Trial for Examining the Therapeutic Equivalence Between Fluticasone Propionate 100 mcg and Salmeterol 50 mcg Inhalation Powder/Respirent Pharmaceuticals vs. ADVAIR DISKUS® 100/50 mcg Inhalation Powder/GSK in Patients With Asthma","status":"COMPLETED","sponsor":"Respirent Pharmaceuticals Co Ltd.","startDate":"2018-10-02","conditions":"Asthma","enrollment":451},{"nctId":"NCT02885025","phase":"PHASE2","title":"Effects of Broccoli Sprout Extract on Allergy Rhinitis","status":"COMPLETED","sponsor":"VA Office of Research and Development","startDate":"2016-10-01","conditions":"Rhinitis,Allergic","enrollment":47},{"nctId":"NCT01881412","phase":"NA","title":"Inhaled Steroids at Discharge After Emergency Department Visits for Children With Uncontrolled Asthma","status":"TERMINATED","sponsor":"Rhode Island Hospital","startDate":"2012-08","conditions":"Asthma","enrollment":118},{"nctId":"NCT02483975","phase":"PHASE3","title":"Effect of Fluticasone Furoate Inhalation Powder on the Hypothalamic-pituitary-adrenocortical Axis of Children Aged 5-11 Years With Asthma","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2015-10-09","conditions":"Asthma","enrollment":111},{"nctId":"NCT02019758","phase":"PHASE4","title":"Budesonide Versus Fluticasone for Treatment of Eosinophilic Esophagitis","status":"COMPLETED","sponsor":"University of North Carolina, Chapel Hill","startDate":"2015-01-01","conditions":"Eosinophilic Esophagitis","enrollment":129},{"nctId":"NCT03207243","phase":"PHASE2","title":"Efficacy and Safety Study of GSK3772847 in Subjects With Moderately Severe Asthma","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2017-09-14","conditions":"Asthma","enrollment":165},{"nctId":"NCT03112577","phase":"PHASE1","title":"Study of REGN3500 and Dupilumab in Patients With Asthma","status":"COMPLETED","sponsor":"Regeneron Pharmaceuticals","startDate":"2017-06-15","conditions":"Asthma, Allergic","enrollment":32},{"nctId":"NCT04208581","phase":"PHASE3","title":"Yiqi Huoxue Huatan Granule for Reducing Mortality in COPD With Chronic Respiratory Failure","status":"UNKNOWN","sponsor":"Peking University People's Hospital","startDate":"2019-10-08","conditions":"Chronic Obstructive Pulmonary Disease, Chronic Respiratory Failure","enrollment":372},{"nctId":"NCT03443843","phase":"PHASE4","title":"A Study to Evaluate Changes in Nasal Airflow of Loratadine/Pseudoephedrine Tablet and Fluticasone Propionate Nasal Spray in Subjects Following Allergen Exposure","status":"COMPLETED","sponsor":"Bayer","startDate":"2018-02-21","conditions":"Rhinitis, Allergic","enrollment":82},{"nctId":"NCT03898466","phase":"PHASE4","title":"Effect of Fluticasone Furoate on Methacholine Challenge","status":"COMPLETED","sponsor":"University of Saskatchewan","startDate":"2018-10-30","conditions":"Asthma","enrollment":14},{"nctId":"NCT00241631","phase":"PHASE2","title":"Enhancement of in-Vitro GC Function in Patients With COPD","status":"COMPLETED","sponsor":"Imperial College London","startDate":"2006-04","conditions":"COPD","enrollment":49},{"nctId":"NCT03535870","phase":"NA","title":"Clinical Endpoint Bioequivalence Study of Fluticasone Propionate & Salmeterol Xinafoate (100μg/50μg)","status":"COMPLETED","sponsor":"West-Ward Pharmaceutical","startDate":"2018-04-26","conditions":"Asthma","enrollment":1556},{"nctId":"NCT01662778","phase":"PHASE4","title":"The Clinical Effect of Monodisperse Fluticasone Propionate in Asthma","status":"COMPLETED","sponsor":"Imperial College London","startDate":"2011-12","conditions":"Asthma","enrollment":21},{"nctId":"NCT00903227","phase":"PHASE4","title":"Steroid Sparing Effect of Nasal Corticosteroid In Asthma And Rhinitis","status":"COMPLETED","sponsor":"University of Dundee","startDate":"2006-12","conditions":"Asthma, Allergic Rhinitis","enrollment":25},{"nctId":"NCT01388595","phase":"PHASE4","title":"Fluticasone and Salmeterol in Allergic Rhinitis","status":"COMPLETED","sponsor":"University of Dundee","startDate":"2006-11","conditions":"Allergic Rhinitis","enrollment":23},{"nctId":"NCT01424397","phase":"PHASE2","title":"Intranasal SB-705498 in Allergic Rhinitis (AR) Patients","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2011-04-14","conditions":"Rhinitis","enrollment":70},{"nctId":"NCT02730351","phase":"PHASE4","title":"Crossover Study Comparing Fluticasone Furoate (FF)/Vilanterol (VI) Once Daily Versus Fluticasone Propionate (FP) Twice Daily in Subjects With Asthma and Exercise-Induced Bronchoconstriction (EIB)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2016-05-25","conditions":"Asthma","enrollment":75},{"nctId":"NCT02729051","phase":"PHASE3","title":"Comparative Study of Fluticasone Furoate(FF)/Umeclidinium Bromide (UMEC)/ Vilanterol (VI) Closed Therapy Versus FF/VI Plus UMEC Open Therapy in Subjects With Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2016-06-29","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":1055},{"nctId":"NCT02496715","phase":"PHASE3","title":"Randomized, Placebo-controlled Study Comparing Efficacy of Fluticasone/Salmeterol Combination to Advair in Asthmatics","status":"WITHDRAWN","sponsor":"Actavis Inc.","startDate":"2015-09","conditions":"Asthma","enrollment":""},{"nctId":"NCT02338362","phase":"PHASE4","title":"Inhaled Corticosteroids: Effect on Intraocular Pressure in Patients With Controlled Glaucoma","status":"COMPLETED","sponsor":"University Health Network, Toronto","startDate":"2014-09","conditions":"Ocular Hypertension, Glaucoma, Open-Angle","enrollment":22},{"nctId":"NCT01194700","phase":"PHASE4","title":"Comparative Study of Lung Bioavailability of HFA-Seretide Via Current Spacer Devices in Healthy Volunteers","status":"COMPLETED","sponsor":"Brian J Lipworth","startDate":"2009-11","conditions":"Asthma","enrollment":19}],"_emaApprovals":[],"_faersSignals":[],"crossReferences":{"chemblId":"CHEMBL1676"},"_approvalHistory":[],"publicationCount":12,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Placebo Flovent® Diskus®","Advair"],"phase":"marketed","status":"active","brandName":"Placebo fluticasone","genericName":"Placebo fluticasone","companyName":"National Institute of Allergy and Infectious Diseases (NIAID)","companyId":"national-institute-of-allergy-and-infectious-diseases-niaid","modality":"Biologic","firstApprovalDate":"","enrichmentLevel":3,"visitCount":0,"regulatoryByCountry":[{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":0,"withResults":0},"validation":{"fieldsValidated":1,"lastValidatedAt":"2026-04-20T02:32:42.134004+00:00","fieldsConflicting":0,"overallConfidence":0.95},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":false,"trials":true,"score":3}}